Showing 1 - 2 results of 2 for search 'Patrick Hlavacek', query time: 0.01s Refine Results
  1. 1
    Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain

    Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispe... by Cristina Encinas, Virginia Lozano, Patrick Hlavacek, Julia Llinares, Sofía Toribio-Castelló, David Carcedo, Jordi Asís-Montalt, Joaquín Martínez-López

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison

    Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison by Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez Cruz, Patrick Hlavacek

    Published 2025-04-01
    Article
    Save to List
    Saved in:

Search Tools: